Introduction
Fungal infections in general and Candida species in particular are increasingly being recognized to cause late onset sepsis(> 3 day) and compete with bacteria today as one of the leading causes of nosocomial infections. 1 Most fungal infections in neonates are due to Candida species; a much smaller number of infections may be attributed to Malassezia, Zygomycetes, or Aspergillus pathogens . Candida produce infections tha.t range from nonlifethreaten ing mucocutaneous illnesses to invasive processes that may involve virtually any organ system . Preterm infants and sick term infants in NICUs have a specific, increased risk for invasive fungal infection.
Incidence
The cumulative incidence of invasive candidiasis is upto 5% of low-birth-weight babies and is inversely proportional to birth weight. 2 About 20% of babies weighing less than 1000 g develop invasive fungal infections. The overall mortality rate for disseminated fungal infections in this group of babies is very high, often approaching 50%. 3 Candida colonization can be detected in approximately 30% of infants weighing less than 1500 g at birth . Colonization increases with decreasing birth weight. 4 · 5 Colonization is not an independent risk factor for subsequent candidiasis . Acquiring Candida does not always translate i· nto systemic infection, but previous colonization is a required step before the occurrence of invas ive candidiasis . 6 Nearly 80% of cases diagnosed in premature infants occur in the first 42 days of life. 7 In term newborns the incidence of candidemia is 10 fold less and is especially related to congenital anomalies especially of the gastrointestinal tract.
Candida Species
Candida organisms are saprophytic yeasts that are ubiquitous and are constituents of the normal microbial flora of humans. All Candida species form pseudohyphae that are important in invasion . Candida 69 albicans is the predominant species associated with maternally acquired neonatal disease . 8 Candida parapsilosis is a common species in nosocomially acquired infection (central line infection), and other species such as Candida stellatoidea, Candida lusitaniae, Candida krusei, and Candida glabrata are reported less frequently. 9 Any Candida species may cause disease in neonates.
Pathogenesis
Neonates may acquire Candida by vertical or nosocomial transmission (person to person contact or via infusates) . In vertical transmission, acquisition may occur either during gestation or at the time of delivery. A combination of infecting dose and host factors play a role in the development of candidiasis. The organism produces multiple virulence factors such as adhesins, proteinases, and phospholipases that promote attachment and invasion . After penetration of epithelial or endothelial barriers, in this setting, Candida can penetrate into lymphatics, blood vessels, and deep tissues, resulting in disseminated infection. Disseminated candidiasis can cause disease in any organ system.
Clinical Manifestations
Clinical manifestations vary depending on the location and extent of the infection . The classic clinical picture of systemic candidiasis in neonates is indistinguishable from bacterial sepsis . 2 Symptoms are often more subtle and indolent. Among these , respiratory dysfunction and apnea were the most common presenting signs in large series. 10 A significant proportion of neonates will present simultaneously with localized signs of candidal infection at one or more sites . In addition to fungaemia, infants may present with pneumonia , meningitis, renal tract infection, endophthalmitis, osteomyelitis, endocarditis, liver abscesses, and skin abscesses . 11 Candida spp. should always be considered in the differential diagnosis of sepsis in the neonate, particularly late onset sepsis. 12 Up to 75% of cases of The most important of these factors appears to be the number of prior antibiotics administered and the duration of therapy. Risk factors for Candida colonization and sepsis are similar neonatal candidiasis present with infection of two or more organs. Malassezia furfur, 1 3 a lipid dependent fungus, is another cause of systemic fungemia in neonates. It frequently involves babies receiving intralipid through a central venous catheter. Lung lesions, pulmonary vasculitis, septic thrombi are the chief affections and the involvement of other organ systems is uncommon. Although Amphotericin B has been used in these cases, they usually resolve on removal of indwelling central catheters and stopping intralipid.
Aspergillosis 13 Contamination through the ventilation system is one of the predisposing factors . One presentation involves the injured skin areas that rapidly (over 24 h) progress to necrotic eschars . Diagnosis is made by demonstrating septate hyphae with 45° angles characteristic of Aspergillus species.
Diagnosis
Documented invasive candidiasis is defined as a positive culture from normally sterile body fluid. No special medium is required for growth of Candida in the laboratory. The isolation of Candida from wounds, skin, urine, or stool specimens is not diagnostic of disease. On the other hand, growth of Candida spp. from sterile specimens (e.g., blood or CSF) is always diagnostic of infection. Candida species grow robustly in the routine blood culture media used in most clinical laboratories, and these media usually yield the organism within 48 to 72 hours of incubation . Widespread infection despite negative cultures is common. 13 Overgrowth of bacteria on nonselective media can easily inhibit or hide the growth of fungi. Selective culture media can be made inhibitory to bacteria by maintaining a low pH (e.g., Sabouraud 
Consequences of missed or delayed diagnosis
Delayed treatment results in increased rates of intraventricular hemorrhage, chronic lung disease, retinopathy of prematurity requiring surgical therapy, and up to a fourfold increase in long-term neurodevelopmental delays. 16 The associated mortality with invasive candidiasis is three times higher than that of uninfected infants of similar gestational age and birth weight. Untreated, the mortality exceeds 80%.
Treatment
Some studies have reported use of empiric antifungals pending culture results, while some have used clinical scores. These have not been studied in prospective controlled trials. There is lack of evidence for routine empiric treatment. In certain circumstances, empiric antifungal therapy for 48-72 hours may be warranted in infants with negative initial culture results who still have signs and symptoms of sepsis after 48 hours of antibacterial treatment and who are recultured. 17 In addition, the infants must have one of the following criteria:
• Thrombocytopenia ( < 100 X 10 9 /L) • Necrotising enterocolitis or focal bowel perforation • Weight of less than 750 g or a gestational age of less than 26 weeks
Definitive treatment 18
Isolation of candida from sterile site warrants definitive therapy. Amphotericin B is the drug of choice for invasive fungal infections. It is effective against most Candida species causing disease in neonates except for C lusitaniae. Test doses are not required because the drug is better tolerated in neonates than in adults.
Age and underlying disease are not associated with increased risk of nephrotoxicity. Lipid formulations of amphotericin B are very expensive and do not appear to be more efficacious than conventional amphotericin B deoxycholate, and their use should be limited to patients who are either refractory to, or intolerant of, the regular amphotericin B preparation Flucytosine is not recommended as monotherapy because resistance develops rapidly, but the antifungal is given occasionally in combination with amphotericin B for central nervous system infections. The lack of a parenteral formulation limits the utility of flucytosine. Fluconazole is both safe and effective for invasive fungal infections. However 50% of C glabrata and 100% of C krusei isolates have been reported to be 'resistant to fluconazole. Breakthrough (or persistence of) candidemia in the face of ongoing antifungal therapy suggests the possibility of an infected intravascular device, significant immunosuppression, or microbiological resistance . Considering the increasing use of newer antifungals in NICUs, available preparations caspo variable should be discussed in greater detail, highlighting their risks .
Duration of treatment
In the absence of deep tissue involvement for abscess formation, treatment is continued 5 to 7 days after clinical improvement. At least 14 days of therapy after the last positive blood-culture result is recommended for neonates with candidemia in the absence of disseminated disease. Prolonged antifungal therapy (ie, 6 weeks) is frequently required for chronic disseminated candidiasis, endocarditis, endophthalmitis, and osteomyelitis. • Use HEPA filtration ventilation systems and take measures for containment of dust populations of < 1000 gram infants, prophylaxis may be appropriate. One concern with fluconazole prophylaxis is the potential for the emergence of resistance over time. Further trials a re needed to establish proplylactic use of antifungal agents.
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